Proximal tubulopathy: Prime mover and key therapeutic target in diabetic kidney disease

Diabetes

Volumn 66, Issue 4, 2017, Pages 791-800

  Gilbert, Richard E ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; CREATININE;

ACUTE KIDNEY FAILURE; AEROBIC METABOLISM; ANGIOGENESIS; CHRONIC KIDNEY FAILURE; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; GLOMERULUS; GLUCONEOGENESIS; HISTOPATHOLOGY; HUMAN; HYPOXIA; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE DISORDER; MORPHOMETRY; NEPHRON; OXYGEN TRANSPORT; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SODIUM ABSORPTION; APOPTOSIS; DISEASE COURSE; FIBROSIS; ISCHEMIA; METABOLISM; MITOCHONDRION; OXYGEN CONSUMPTION;

APOPTOSIS; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FIBROSIS; HUMANS; HYPOXIA; ISCHEMIA; KIDNEY GLOMERULUS; KIDNEY TUBULES, PROXIMAL; MITOCHONDRIA; OXYGEN CONSUMPTION; RENAL INSUFFICIENCY, CHRONIC;

EID: 85019555027     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db16-0796     Document Type: Review

References (82)

1. Kimmelstiel P, Wilson C. Intercapillary lesions in the glomerulus. Am J Pathol 1936;12:83-97, 7
2. Krolewski AS. Progressive renal decline: The new paradigm of diabetic nephropathy in type 1 diabetes. Diabetes Care 2015;38:954-962
3. Fenton RA, Praetorius J. Anatomy of the kidney. In Brenner and Rectors The Kidney. Taal MW, Chertow GM, Marsden PA, Skorecki K, Yu SL, Brener BM, Eds. Philadelphia, PA, Elsevier, 2016
4. Gilbert RE, Cooper ME. The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int 1999;56:1627-1637
5. Marcussen N. Tubulointerstitial damage leads to atubular glomeruli: significance and possible role in progression. Nephrol Dial Transplant 2000;15 (Suppl. 6):74-75
6. Najafian B, Kim Y, Crosson JT, Mauer M. Atubular glomeruli and glomerulotubular junction abnormalities in diabetic nephropathy. J Am Soc Nephrol 2003;14:908-917
7. White KE, Marshall SM, Bilous RW. Prevalence of atubular glomeruli in type 2 diabetic patients with nephropathy. Nephrol Dial Transplant 2008;23:3539-3545
8. Hasegawa K, Wakino S, Simic P, et al. Renal tubular Sirt1 attenuates diabetic albuminuria by epigenetically suppressing Claudin-1 overexpression in podocytes. Nat Med 2013;19:1496-1504
9. Nihalani D, Susztak K. Sirt1-Claudin-1 crosstalk regulates renal function. Nat Med 2013;19:1371-1372
10. Romagnani P, Remuzzi G. Renal progenitors in non-diabetic and diabetic nephropathies. Trends Endocrinol Metab 2013;24:13-20
11. Bonventre JV. Can we target tubular damage to prevent renal function decline in diabetes? Semin Nephrol 2012;32:452-462
12. Grgic I, Campanholle G, Bijol V, et al. Targeted proximal tubule injury triggers interstitial fibrosis and glomerulosclerosis. Kidney Int 2012;82:172-183
13. Kumar D, Robertson S, Burns KD. Evidence of apoptosis in human diabetic kidney. Mol Cell Biochem 2004;259:67-70
14. Saharfuddin AA, Weisbord SD, Palevsky PM, Molitoris BA. Acute kidney injury. In Brenner and Rectors The Kidney. Taal MW, Chertow GM, Marsden PA, Skorecki K, Yu SL, Brener BM, Eds. Philadelphia, PA, Elsevier, 2016, p. 958-1011
15. Yang L, Besschetnova TY, Brooks CR, Shah JV, Bonventre JV: Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat Med 2010;16:535-543
16. Basile DP, Friedrich JL, Spahic J, et al. Impaired endothelial proliferation and mesenchymal transition contribute to vascular rarefaction following acute kidney injury. Am J Physiol Renal Physiol 2011;300:F721-F733
17. Lan R, Geng H, Polichnowski AJ, et al. PTEN loss defines a TGF-b-induced tubule phenotype of failed differentiation and JNK signaling during renal fibrosis. Am J Physiol Renal Physiol 2012;302:F1210-F1223
18. Thakar CV, Christianson A, Himmelfarb J, Leonard AC. Acute kidney injury episodes and chronic kidney disease risk in diabetes mellitus. Clin J Am Soc Nephrol 2011;6:2567-2572
19. Monseu M, Gand E, Saulnier PJ, et al.; SURDIAGENE Study Group. Acute kidney injury predicts major adverse outcomes in diabetes: synergic impact with low glomerular filtration rate and albuminuria. Diabetes Care 2015;38:2333-2340
20. Weir MR, Januszewicz A, Gilbert RE, et al. Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus. J Clin Hypertens (Greenwich) 2014;16:875-882
21. Cherney DZ, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014;129:587-597
22. Wanner C, Inzucchi SE, Lachin JM, et al.; EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016;375:323-334
23. Gilbert RE. SGLT2 inhibitors: b blockers for the kidney? Lancet Diabetes Endocrinol 2016;4:814
24. Zinman B, Wanner C, Lachin JM, et al.; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-2128
25. Macisaac RJ, Jerums G. Diabetic kidney disease with and without albuminuria. Curr Opin Nephrol Hypertens 2011;20:246-257
26. Ferguson MA, Waikar SS. Established and emerging markers of kidney function. Clin Chem 2012;58:680-689
27. Fufaa GD, Weil EJ, Nelson RG, et al.; Chronic Kidney Disease Biomarkers Consortium Investigators. Association of urinary KIM-1, L-FABP, NAG and NGAL with incident end-stage renal disease and mortality in American Indians with type 2 diabetes mellitus. Diabetologia 2015;58:188-198
28. Panduru NM, Sandholm N, Forsblom C, et al.; FinnDiane Study Group. Kidney injury molecule-1 and the loss of kidney function in diabetic nephropathy: A likely causal link in patients with type 1 diabetes. Diabetes Care 2015;38: 1130-1137
29. Sabbisetti VS, Waikar SS, Antoine DJ, et al. Blood kidney injury molecule-1 is a biomarker of acute and chronic kidney injury and predicts progression to ESRD in type I diabetes. J Am Soc Nephrol 2014;25:2177-2186
30. Nowak N, Skupien J, Niewczas MA, et al. Increased plasma kidney injury molecule-1 suggests early progressive renal decline in non-proteinuric patients with type 1 diabetes. Kidney Int 2016;89:459-467
31. Charlton JR, Portilla D, Okusa MD. A basic science view of acute kidney injury biomarkers. Nephrol Dial Transplant 2014;29:1301-1311
32. Nielsen SE, Sugaya T, Tarnow L, et al. Tubular and glomerular injury in diabetes and the impact of ACE inhibition. Diabetes Care 2009;32:1684-1688
33. Nielsen SE, Sugaya T, Hovind P, Baba T, Parving HH, Rossing P. Urinary liver-Type fatty acid-binding protein predicts progression to nephropathy in type 1 diabetic patients. Diabetes Care 2010;33:1320-1324
34. Araki S, Haneda M, Koya D, et al. Predictive effects of urinary liver-Type fatty acid-binding protein for deteriorating renal function and incidence of cardiovascular disease in type 2 diabetic patients without advanced nephropathy. Diabetes Care 2013;36:1248-1253
35. Panduru NM, Forsblom C, Saraheimo M, et al.; FinnDiane Study Group. Urinary liver-Type fatty acid-binding protein and progression of diabetic nephropathy in type 1 diabetes. Diabetes Care 2013;36:2077-2083
36. Fiseha T, Tamir Z. Urinary markers of tubular injury in early diabetic nephropathy. Int J Nephrol 2016;2016:4647685
37. Vaidya VS, Niewczas MA, Ficociello LH, et al. Regression of microalbuminuria in type 1 diabetes is associated with lower levels of urinary tubular injury biomarkers, kidney injury molecule-1, and N-Acetyl-beta-D-glucosaminidase. Kidney Int 2011;79:464-470
38. Fine LG, Orphanides C, Norman JT. Progressive renal disease: The chronic hypoxia hypothesis. Kidney Int Suppl 1998;65:S74-S78
39. Laustsen C, Østergaard JA, Lauritzen MH, et al. Assessment of early diabetic renal changes with hyperpolarized [1-(13) C]pyruvate. Diabetes Metab Res Rev 2013;29:125-129
40. Khan S, Cleveland RP, Koch CJ, Schelling JR. Hypoxia induces renal tubular epithelial cell apoptosis in chronic renal disease. Lab Invest 1999;79:1089-1099
41. Fine LG, Norman JT. Chronic hypoxia as a mechanism of progression of chronic kidney diseases: from hypothesis to novel therapeutics. Kidney Int 2008; 74:867-872
42. Mimura I, Nangaku M. The suffocating kidney: Tubulointerstitial hypoxia in end-stage renal disease. Nat Rev Nephrol 2010;6:667-678
43. Orphanides C, Fine LG, Norman JT. Hypoxia stimulates proximal tubular cell matrix production via a TGF-beta1-independent mechanism. Kidney Int 1997;52: 637-647
44. Singh P, McDonough AA, Thomson SA. Metabolic basis of solute transport. In Brenner and Rectors The Kidney. Taal MW, Chertow GM, Marsden PA, Skorecki K, Yu SL, Brener BM, Eds. Philadelphia, PA, Elsevier, 2016, p. 122-143
45. DeFronzo RA, Hompesch M, Kasichayanula S, et al. Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care 2013;36:3169-3176
46. Körner A, Eklöf AC, Celsi G, Aperia A. Increased renal metabolism in diabetes. Mechanism and functional implications. Diabetes 1994;43:629-633
47. Chang YK, Choi H, Jeong JY, et al. Dapagliflozin, SGLT2 inhibitor, attenuates renal ischemia-reperfusion injury. PLoS One 2016;11:e0158810
48. Saad S, Zhang J, Yong R, et al. Role of the EGF receptor in PPARg-mediated sodium and water transport in human proximal tubule cells. Diabetologia 2013; 56:1174-1182
49. Laustsen C, Lipsø K, Ostergaard JA, et al. Insufficient insulin administration to diabetic rats increases substrate utilization and maintains lactate production in the kidney. Physiol Rep 2014;2:e12233
50. Cohen JJ. Relationship between energy requirements for Na+ reabsorption and other renal functions. Kidney Int 1986;29:32-40
51. Guder WG, Ross BD. Enzyme distribution along the nephron. Kidney Int 1984;26:101-111
52. Meyer C, Dostou JM, Welle SL, Gerich JE. Role of human liver, kidney, and skeletal muscle in postprandial glucose homeostasis. Am J Physiol Endocrinol Metab 2002;282:E419-E427
53. Meyer C, Stumvoll M, Nadkarni V, Dostou J, Mitrakou A, Gerich J. Abnormal renal and hepatic glucose metabolism in type 2 diabetes mellitus. J Clin Invest 1998;102:619-624
54. Meyer C, Woerle HJ, Dostou JM, Welle SL, Gerich JE. Abnormal renal, hepatic, and muscle glucose metabolism following glucose ingestion in type 2 diabetes. Am J Physiol Endocrinol Metab 2004;287:E1049-E1056
55. Blantz RC. Phenotypic characteristics of diabetic kidney involvement. Kidney Int 2014;86:7-9
56. Zhao L, Gao H, Lian F, Liu X, Zhao Y, Lin D. 1H-NMR-based metabonomic analysis of metabolic profiling in diabetic nephropathy rats induced by streptozotocin. Am J Physiol Renal Physiol 2011;300:F947-F956
57. Hötter JF, Schweickhardt C, Piper HM, Spieckermann PG. Inhibition of fatty acid oxidation and decrease of oxygen consumption of working rat heart by 4-bromocrotonic acid. J Mol Cell Cardiol 1984;16:105-108
58. Zhan M, Brooks C, Liu F, Sun L, Dong Z. Mitochondrial dynamics: regulatory mechanisms and emerging role in renal pathophysiology. Kidney Int 2013;83: 568-581
59. Zhan M, Usman IM, Sun L, Kanwar YS. Disruption of renal tubular mitochondrial quality control by Myo-inositol oxygenase in diabetic kidney disease. J Am Soc Nephrol 2015;26:1304-1321
60. Coughlan MT, Nguyen TV, Penfold SA, et al. Mapping time-course mitochondrial adaptations in the kidney in experimental diabetes. Clin Sci (Lond) 2016;130:711-720
61. Haigis MC, Sinclair DA. Mammalian sirtuins: biological insights and disease relevance. Annu Rev Pathol 2010;5:253-295
62. Baumgartner-Parzer SM, Wagner L, Pettermann M, Grillari J, Gessl A, Waldhäusl W. High-glucose-Triggered apoptosis in cultured endothelial cells. Diabetes 1995;44:1323-1327
63. Ho FM, Liu SH, Liau CS, Huang PJ, Lin-Shiau SY. High glucose-induced apoptosis in human endothelial cells is mediated by sequential activations of c-Jun NH(2)-Terminal kinase and caspase-3. Circulation 2000;101:2618-2624
64. Osterby R, Parving HH, Nyberg G, et al. A strong correlation between glomerular filtration rate and filtration surface in diabetic nephropathy. Diabetologia 1988;31:265-270
65. Bohle A, Mackensen-Haen S, Wehrmann M. Significance of postglomerular capillaries in the pathogenesis of chronic renal failure. Kidney Blood Press Res 1996;19:191-195
66. Eardley KS, Kubal C, Zehnder D, et al. The role of capillary density, macrophage infiltration and interstitial scarring in the pathogenesis of human chronic kidney disease. Kidney Int 2008;74:495-504
67. Lindenmeyer MT, Kretzler M, Boucherot A, et al. Interstitial vascular rarefaction and reduced VEGF-A expression in human diabetic nephropathy. J Am Soc Nephrol 2007;18:1765-1776
68. Gilbert RE. Endothelial loss and repair in the vascular complications of diabetes: pathogenetic mechanisms and therapeutic implications. Circ J 2013;77:849-856
69. Yuen DA, Connelly KA, Advani A, et al. Culture-modified bone marrow cells attenuate cardiac and renal injury in a chronic kidney disease rat model via a novel antifibrotic mechanism. PLoS One 2010;5:e9543
70. Skyler JS, Fonseca VA, Segal KR, Rosenstock J; MSB-DM003 Investigators. Allogeneic mesenchymal precursor cells in type 2 diabetes: A randomized, placebocontrolled, dose-escalation safety and tolerability pilot study. Diabetes Care 2015;38: 1742-1749
71. Packham DK, Fraser IR, Kerr PG, Segal KR. Allogeneic mesenchymal precursor cells (MPC) in diabetic nephropathy: A randomized, placebo-controlled, dose escalation study. EBioMedicine 2016;12:263-269
72. Kikuchi Y, Ito K, Ito Y, et al. Double-blind and placebo-controlled study of the effectiveness and safety of extracorporeal cardiac shock wave therapy for severe angina pectoris. Circ J 2010;74:589-591
73. Zhang X, Krier JD, Amador Carrascal C, et al. Low-energy shockwave therapy improves ischemic kidney microcirculation. J Am Soc Nephrol 2016;27: 3715-3724
74. Gilbert RE, Advani A. Vasoactive molecules and the kidney. In Brenner and Rectors The Kidney. Taal MW, Chertow GM, Marsden PA, Skorecki K, Yu SL, Brener BM, Eds. Philadelphia, PA, Elsevier, 2016, p. 325-353
75. Allison SJ. Fibrosis: dysfunctional fatty acid oxidation in renal fibrosis. Nat Rev Nephrol 2015;11:64
76. Parker MD, Myers EJ, Schelling JR. Na+-H+ exchanger-1 (NHE1) regulation in kidney proximal tubule. Cell Mol Life Sci 2015;72:2061-2074
77. Forrester SJ, Kawai T, OBrien S, Thomas W, Harris RC, Eguchi S. Epidermal growth factor receptor transactivation: mechanisms, pathophysiology, and potential therapies in the cardiovascular system. Annu Rev Pharmacol Toxicol 2016; 56:627-653
78. Szeto SG, Narimatsu M, Lu M, et al. YAP/TAZ are mechanoregulators of TGF-b-Smad signaling and renal fibrogenesis. J Am Soc Nephrol. 9 March 2016 [Epub ahead of print]
79. Santucci M, Vignudelli T, Ferrari S, et al. The Hippo pathway and YAP/TAZTEAD protein-protein interaction as targets for regenerative medicine and cancer treatment. J Med Chem 2015;58:4857-4873
80. Owens J. Target validation: determining druggability. Nat Rev Drug Discov 2007;6:187
81. Tisher CC, Rosen S, Osborne GB. Ultrastructure of the proximal tubule of the rhesus monkey kidney. Am J Pathol 1969;56:469-517
82. Chao EC, Henry RR. SGLT2 inhibition-A novel strategy for diabetes treatment. Nat Rev Drug Discov 2010;9:551-559